Market Update (NASDAQ:AMGN): Amgen Announces Positive Top-Line Results From Phase 3 Study Evaluating The Efficacy And Safety Of Biosimilar Candidate ABP 501 Compared With Adalimumab In Patients With Moderate-To-Severe Plaque Psoriasis

[PR Newswire] – THOUSAND OAKS, Calif., Oct. 8, 2014 /PRNewswire/ — Amgen (AMGN) today announced its Phase 3 study evaluating efficacy and safety of biosimilar candidate ABP 501 compared with Humira® (adalimumab) in . . . → Read More: Market Update (NASDAQ:AMGN): Amgen Announces Positive Top-Line Results From Phase 3 Study Evaluating The Efficacy And Safety Of Biosimilar Candidate ABP 501 Compared With Adalimumab In Patients With Moderate-To-Severe Plaque Psoriasis Similar Articles: Market Update: Amgen Inc (NASDAQ:AMGN) – Lilly psoriasis drug impresses; battle nears with Amgen, Novartis Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Webcast of 2014 Second Quarter Financial Results Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Webcast of 2014 First Quarter Financial Results